Kaken Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Kaken Pharmaceutical has a total shareholder equity of ¥142.5B and total debt of ¥3.9B, which brings its debt-to-equity ratio to 2.7%. Its total assets and total liabilities are ¥174.8B and ¥32.3B respectively. Kaken Pharmaceutical's EBIT is ¥9.0B making its interest coverage ratio -17.9. It has cash and short-term investments of ¥66.6B.
Key information
2.7%
Debt to equity ratio
JP¥3.85b
Debt
| Interest coverage ratio | -17.9x |
| Cash | JP¥66.56b |
| Equity | JP¥142.52b |
| Total liabilities | JP¥32.26b |
| Total assets | JP¥174.78b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: KKPC.F's short term assets (¥109.1B) exceed its short term liabilities (¥23.1B).
Long Term Liabilities: KKPC.F's short term assets (¥109.1B) exceed its long term liabilities (¥9.2B).
Debt to Equity History and Analysis
Debt Level: KKPC.F has more cash than its total debt.
Reducing Debt: KKPC.F's debt to equity ratio has reduced from 3.2% to 2.7% over the past 5 years.
Debt Coverage: KKPC.F's debt is well covered by operating cash flow (66.9%).
Interest Coverage: KKPC.F earns more interest than it pays, so coverage of interest payments is not a concern.